Skip to main content
SpringerLink
Log in

An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, Caletti MT, Aiello V, Cianciolo G, la Manna G (2019) New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol:1–12. https://doi.org/10.1007/s40620-019-00600-7

  2. Kolkhof P, Barfacker L (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of endocrinology 234 (1):T125–T140

    Article  CAS  PubMed  Google Scholar 

  3. Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414. https://doi.org/10.1007/s11906-013-0414-8

    Article  CAS  PubMed  Google Scholar 

  4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199909023411001

    Article  CAS  PubMed  Google Scholar 

  5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019

    Article  PubMed  Google Scholar 

  6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–ee61. https://doi.org/10.1161/CIR.0000000000000509

    Article  PubMed  Google Scholar 

  7. Medicines.org.uk (2019) Spironolactone - summary of product characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/ingredient/36. Accessed 26 June 2019

  8. Agencia Española de Medicamentos y Productos Sanitarios - AEMPS (2019) Espironolactona - Summary of Product Characteristics (SPC). https://cima.aemps.es/cima/publico/lista.html. Accessed 26 June 2019

  9. Swedish Medical Products Agency (2019) Spironolakton -summary of product characteristics (SPC). https://lakemedelsverket.se/LMF/?q=Spironolakton&type=product. Accessed 27 June 2019

  10. Agenzia Italiana del Farmaco - AIFA (2019) Luvion - Riassunto delle caratteristiche del prodotto. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000913_024273_RCP.pdf&retry=0&sys=m0b1l3. Assessed 26 Aug 2019

  11. Medicines Evaluation Board (2019) Spironolacton - summary of product characteristics (SPC) https://www.geneesmiddeleninformatiebank.nl/nl/. Accessed 30 June 2019

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Unit for Clinical Pharmacology, University Hospital “Sveti Duh”, Sveti Duh, 64, Zagreb, Croatia

    Ivana Mikačić

  2. Department of Internal Medicine, School of Medicine, University of Zagreb, Šalata 3, Zagreb, Croatia

    Ivana Mikačić

Authors
  1. Ivana Mikačić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivana Mikačić.

Ethics declarations

Conflict of interest

The author declares that she has no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 19.3 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mikačić, I. An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?. Eur J Clin Pharmacol 76, 131–132 (2020). https://doi.org/10.1007/s00228-019-02774-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-019-02774-2

Keywords

Search

Navigation